Neurocritical Care News

Kriya Therapeutics Inc. announced the acquisition of biotech company Redpin Therapeutics Inc., bolstering Kriya’s neurology therapeutic portfolio by adding gene therapy programs for epilepsy and trigeminal neuralgia.

A team of researchers at the University of Miami Miller School of Medicine have developed an online platform of metrics designed to assess a patient’s risk for developing Alzheimer’s disease and other neurological issues.

The Pershing Square Foundation announced the launch of the Maximizing Innovation in Neuroscience Discover prize to establish a community of multidisciplinary investigators who can improve understanding of the brain and cognition.

Treatment with inebilizumab was associated with reduction in aquaporin-4 antibody titers and B cells for those with neuromyelitis optica spectrum disorder, according to an expert at ECTRIMS 2022.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.

Viz.ai has announced that 85% of aneurysms detected by Viz Aneurysm, its artificial intelligence-based detection tool, previously had not been referred for neurovascular review.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

CHICAGO — A history of two or more head injuries was associated with mild behavioral impairment in older adults, according to a poster presentation at the 2022 American Neurological Association annual meeting.